Biofortuna

Over 200 people from the Northwest’s biomedical sector gathered last night (Thursday 12th November) at the prestigious annual Northwest Biomedical Awards at Mere Golf and Country Club.  The awards, organised by Bionow, the Northwest Regional Development Agency’s (NWDA) biomedical cluster support group, were a resounding success and showcased the very best of the region’s world [...]

Read full news story »

Biofortuna secure an offer of £94,558 from the Northwest Development Agency in a grant for Research & Development. The grant will enable Biofortuna to develop a novel DNA genotyping method that has the potential to allow healthcare professionals to look at multiple gene mutations simultaneously in one rapid test.
(Also featured in the Bionow May newsletter)

Read full news story »

Mark Reardon and Andy Bonner join Biofortuna as Software Development manager and Operations manager respectively.
(Also featured on the Merseybio website)

Read full news story »

Following successful proof of concept work AFM through the Liverpool Seed Fund inject £450,000 into Biofortuna in two rounds of funding to complete the proof of concept and commercialisation phases.
(Also featured on the Liverpool Daily Post website)

Read full news story »

Biofortuna founding directors David Charvill and Ben Passey begin setting up laboratories at the MerseyBio incubator facility. Ben Passey, said “The MerseyBIO Incubator is a fantastic resource for local start-up companies. It offers flexible, affordable lab and office space as well as great support services which really help fledgling companies get off to a great [...]

Read full news story »

Biofortuna secures an initial round of funding from the Merseyside Special Investment Fund via Liverpool Ventures.
The Biofortuna team is made up of founder directors Mike Bunce, David Charvill and Ben Passey, previously of Wirral based Invitrogen, formerly Dynal Biotech Ltd.

Read full news story »